# A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer

Source: https://onco.cc/trials/nct02671955/  
OnCo record `nct02671955` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of CI-8993 run by Janssen Research & Development, LLC, terminated.

## Summary

A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer is a phase 1 interventional study registered as NCT02671955 by Janssen Research & Development, LLC, with 12 participants enrolled, started 2016-01. Conditions recorded: Advanced Cancer. Interventions recorded: JNJ-61610588.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02671955
- Phase: 1
- Setting: An Open-label, First-in-Human, Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-61610588, a Fully Human IgG1 Kappa Anti-VISTA (V-domain Ig Suppressor of T-cell Activation) Monoclonal Antibody, in Subjects With Advanced Cancer
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 12

## Sources

- ClinicalTrials.gov NCT02671955: https://clinicaltrials.gov/study/NCT02671955

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [CI-8993](https://onco.cc/drugs/ci-8993/)
- companies: [Curis](https://onco.cc/companies/curis/), [ImmuNext](https://onco.cc/companies/immunext/), [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct02671955.json